

Amersham Cy3 Mono-Reactive Dye Pack

Reagents for the labelling of biological compounds with CyTM3 monofunctional dye

Product Specification Sheet

Code: PA23001

Warning

For research use only.

Not recommended or intended for diagnosis of disease in humans or animals.

Do not use internally or externally in humans or animals

Storage

Store refrigerated at 2–8°C in the dark. Do not use if desiccant capsule in foil pack is either pink or green.

Expiry

See outer packaging.

Components

- Cy3 mono-reactive dye 5 foil packs each containing dried dye to label 1 mg of protein.
- Instructions for use.

Other materials required

- Conjugation buffer: 0.1 M Sodium Carbonate buffer (pH 9.3)
- Separation column containing a filtration gel (sephadexTM, G-25 for antibodies and G-50 for oligonucleotides)
- Separation buffer: Phosphate-buffered Saline, pH 7.2, containing 0.1% Sodium Azide
- Test tubes, transfer pipettes, glassware

Safety warnings and precautions

All chemicals should be considered as potentially hazardous. We therefore recommend that this product is handled only by those persons who have been trained in laboratory techniques and that it is used in accordance with the principles of good laboratory practice. Wear suitable protective clothing such as laboratory overalls, safety glasses and gloves. Care should be taken to avoid contact with skin or eyes. In the case of contact with skin or eyes wash immediately with water. See material safety data sheet(s) and/or safety statement(s) for specific advice.


Caution: This dye is intensely colored and very reactive. Care should be exercised when handling the dye vial to avoid staining clothing, skin and other items.

Introduction

Cyanine reagents have been shown to be useful as fluorescent labels for biological compounds (1, 5). These dyes are intensely fluorescent and highly water soluble, providing significant advantages over other existing fluorophores (4).

The Cy3 dye is an orange fluorescing cyanine that produces an intense signal easily detected using most rhodamine filter sets. The Cy3 dye supplied here is a monofunctional NHS-Ester, and is provided in a dried, pre-measured form ready for the labelling of compounds containing free amino groups.

Figure 1. Cy3 monofunctional dye



Recommended procedure for use

This protocol has been designed for the preparation of Cy3-labelled IgG antibodies. It is designed to label 1 mg protein to a final molar dye/protein (D/P) ratio between 4 and 12. This assumes an average protein molecular weight of 155 000 Daltons. Other D/P ratios can be obtained by using different amounts of protein.

NOTE: The following materials and procedures have been optimized for IgG antibodies. Other proteins may also be readily labelled, however, choice of buffers, separation media, and technique may vary in order to produce optimal results.

Altering the protein concentration and reaction pH will change the labelling efficiency of the reaction. Optimal labelling generally occurs at pH 9.3. Proteins have been successfully labelled with this dye at a pH as low as 7.3, however, labelling times must be significantly longer at lower pH (1). Higher protein concentrations usually increase labelling efficiency. Solutions of up to 10 mg/ml protein have produced good conjugation reactions.

1. Conjugation of dye to antibody

Antibody to be conjugated should be dissolved at 1 mg/ml in Sodium Carbonate-Sodium Bicarbonate buffer (2). Add the protein solution (1 ml) to the dye vial, cap the vial, and mix thoroughly. Care should be taken to prevent foaming of the protein solution. Incubate the reaction at room temperature for 30 minutes with additional mixing approximately every 10 minutes.

NOTE: Buffers containing primary amino groups such as TRIS and glycine will inhibit the conjugation reaction. The presence of low concentrations (<2%) of biocides such as Azide or Thimerosal do not affect protein labelling.

2. Separation of protein from free dye

Labelled antibody can be separated from the excess, unconjugated dye by gel permeation chromatography. It is convenient to pre-equilibrate the column with Phosphate-buffered Saline and to elute the protein using the same buffer. Two pink bands should develop during elution. The faster moving band is Cy3-labelled antibody while the slower band is free dye. Many Cy3-labelled proteins can be stored at 2–8°C without further manipulation.

Labelled antibody can also be separated from unconjugated dye by dialysis. Dialysis does not give as efficient and rapid a separation as gel filtration. We therefore recommend that protein purification by gel filtration be used.



3. Estimation of final dye/protein (D/P) ratio

Dilute a portion of the labelled protein solution so that the maximum absorbance is 0.5 to 1.5 AU. Molar concentrations of dye and protein are calculated, and the ratio of these values is the average number of dye molecules coupled to each protein molecule. Molar extinction coefficients of 150 000 M⁻¹ cm⁻¹ at 552 nm for the Cy3 dye and 170 000 M⁻¹ cm at 280 nm for the protein are used in this example. The extinction coefficient will vary for different proteins. The calculation is corrected for the absorbance of the dye at 280 nm (approximately 8% of the absorbance at 552 nm).

$$[\text{Cy3 dye}] = (A_{552}) / 150\,000$$

$$[\text{antibody}] = (A_{280} \cdot (0.08 \cdot (A_{552}))) / 170\,000$$

$$(D/P)_{\text{final}} = [\text{dye}] / [\text{antibody}]$$

$$(D/P)_{\text{final}} = (1.13 \cdot (A_{552})) / (A_{280} \cdot (0.08 \cdot (A_{552})))$$

4. Conjugation of dye to oligonucleotides

Modified oligonucleotides containing alkyl amino groups can be labelled with cyanine dye. Synthetic oligonucleotides must be deprotected before conjugation. Procedures that use concentrated Ammonium Hydroxide require the following pretreatment to remove all traces of Ammonia.

Concentrate the sample until it is dry (a vacuum concentrator works effectively).

Dissolve the sample in 0.25 ml of a 0.5 M Sodium Chloride solution and separate using an appropriate desalting column (Sephadex G-50) equilibrated with a 5.0 mM borate buffer solution adjusted to a pH of 8.0. Elute the sample with above borate buffer solution.

Concentrate the sample until it is dry. Dissolve the dry sample in a 0.1 M carbonate buffer (pH 8.5-9.0).


Conjugation is carried out by adding 30 nmoles of oligonucleotide sample in approximately 0.5 ml of carbonate buffer to the dye vial. Cap the vial and mix thoroughly. Incubate the reaction at room temperature for 60 minutes with additional mixing at 15 minute intervals.

5. Separation of labelled oligonucleotides

Conjugated oligonucleotides can be separated from free dye using the same gel filtration procedures listed for separating conjugated antibody. A gel with a smaller exclusion size (such as Sephadex G-50) and a longer column length must be used with shorter oligonucleotides in order to ensure complete separation.

Cy3-labelled oligonucleotides can be separated from unconjugated oligonucleotides using RP-HPLC. The general procedure listed in reference 3 may be optimized for the specific nucleotide sequence and HPLC configuration.

Figure 2. Cy3 dye absorption and fluorescence spectra



Cy3 monofunctional dye characteristics

Formula weight	765.95
Absorbance max	550 nm
Extinction max	150 000 M ⁻¹ cm ⁻¹
Emission max	570 nm
Quantum yield	>0.15*

* for labelled proteins, D/P = 2

References

1. Mujumdar, R.B. *et al.*, *Bioconjugate Chemistry* **4** (2), 105-111 (1993).
2. Southwick, P.L. *et al.*, *Cytometry* **11**, 418-430 (1990).
3. Smith, L.M. *et al.*, *Nucleic Acids Research* **13**, 2399-2412 (1985).
4. Wessendorf, M.W. and Brelje, T.C., *Histochemistry* **98** (2), 81-85 (1992).
5. Yu, H. *et al.*, *Nucleic Acids Research* **22** (15), 3226-3232 (1994).

Related products

Cy5 Mono-Reactive Dye Pack	PA25001
Cy3 Maleimide Mono-Reactive Dye 5-Pack	PA23031
Cy5 Maleimide Mono-Reactive Dye 5-Pack	PA25031

Legal

GE and GE Monogram are trademarks of General Electric Company

Amersham, Cy and Sephadex are trademarks of GE Healthcare companies

This product or portions thereof is manufactured under licence from Carnegie Mellon University, US Patent Numbers 5268486, 5569587 and 5627027

© 2007 General Electric Company – All rights reserved.

GE Healthcare reserves the right, subject to any regulatory and contractual approval, if required, to make changes in specification and features shown herein, or discontinue the product described at any time without notice or obligation.

Contact your GE Healthcare representative for the most current information and a copy of the terms and conditions.

www.gehealthcare.com/lifesciences

GE Healthcare UK Limited
Amersham Place, Little Chalfont,
Buckinghamshire, HP7 9NA UK

GE Healthcare Bio-Sciences AB
Björkgatan 30 751 84,
Uppsala Sweden

GE Healthcare Europe GmbH
Munzinger Strasse 5 D-79111,
Freiburg Germany

GE Healthcare Bio-Sciences Corp
800 Centennial Avenue PO Box 1327,
Piscataway NJ 08855-1327 USA

GE Healthcare Bio-Sciences KK
Sanken Bldg 3-25-1, Hyakunincho Shinjuku-ku,
Tokyo 169-0073 Japan



imagination at work